Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

By sjmartinez • February 4, 2024

Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Zahlten-Kümeli A, Taylor K, Enzinger PC. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 Feb 3. doi: 10.1007/s10120-024-01466-w. Epub ahead of print. PMID: 38308771.

Tags: Bemarituzumab, Fgfr2b, gastric cancer, Hematology/Oncology, mFOLFOX6, Publications, targeted therapy

Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

Shibata T, Bhat S, Cao D, Saito S, Khan N, Bernstein EA, Tokudome T, Okwan-Duodu D, Tourtellotte WG, Bernstein KE, Khan Z. Bioengineered iPSC-derived human[...]

First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Stud

Gray JE, Neal JW, Patel JD, Liu SV, Veillon R, Reck M, Cappuzzo F, Cobo M, Reguart N, Fuentes Pradera J, Cho BC, Mok T,[...]

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape

Hennessy MA, Terman E, Idossa D, LeVee A, Leon-Ferre RA, McArthur H, Nanda R. Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.[...]